JP2025500880A5 - - Google Patents

Info

Publication number
JP2025500880A5
JP2025500880A5 JP2024535741A JP2024535741A JP2025500880A5 JP 2025500880 A5 JP2025500880 A5 JP 2025500880A5 JP 2024535741 A JP2024535741 A JP 2024535741A JP 2024535741 A JP2024535741 A JP 2024535741A JP 2025500880 A5 JP2025500880 A5 JP 2025500880A5
Authority
JP
Japan
Prior art keywords
lyme disease
disease vaccine
vaccine according
molar ratio
ospa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024535741A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025500880A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/086341 external-priority patent/WO2023111262A1/en
Publication of JP2025500880A publication Critical patent/JP2025500880A/ja
Publication of JP2025500880A5 publication Critical patent/JP2025500880A5/ja
Pending legal-status Critical Current

Links

JP2024535741A 2021-12-17 2022-12-16 ライム病rnaワクチン Pending JP2025500880A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21315283.8 2021-12-17
EP21315283 2021-12-17
EP21315291 2021-12-23
EP21315291.1 2021-12-23
PCT/EP2022/086341 WO2023111262A1 (en) 2021-12-17 2022-12-16 Lyme disease rna vaccine

Publications (2)

Publication Number Publication Date
JP2025500880A JP2025500880A (ja) 2025-01-15
JP2025500880A5 true JP2025500880A5 (cg-RX-API-DMAC10.html) 2025-12-22

Family

ID=84923336

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024535741A Pending JP2025500880A (ja) 2021-12-17 2022-12-16 ライム病rnaワクチン

Country Status (7)

Country Link
US (1) US20250009863A1 (cg-RX-API-DMAC10.html)
EP (1) EP4448103A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025500880A (cg-RX-API-DMAC10.html)
CN (1) CN119095613A (cg-RX-API-DMAC10.html)
AU (1) AU2022413622A1 (cg-RX-API-DMAC10.html)
CA (1) CA3242439A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023111262A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024215721A1 (en) * 2023-04-10 2024-10-17 Modernatx, Inc. Lyme disease vaccines
WO2025134046A1 (en) * 2023-12-22 2025-06-26 Pfizer Inc. Methods and vaccine compositions for lyme disease
WO2025210592A1 (en) 2024-04-05 2025-10-09 Sanofi Pasteur Inc. Muscle cell lnp-mrna quality control assays
WO2026080379A1 (en) * 2024-10-07 2026-04-16 Modernatx, Inc. Lyme disease mrna vaccines

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
PT1751289E (pt) 2004-05-18 2009-03-31 Alphavax Inc Vectores de alfavirais derivados da tc-83, partículas e métodos
EP2451475A2 (en) 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
SI2506857T1 (en) 2009-12-01 2018-08-31 Translate Bio, Inc. Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
EA201492055A1 (ru) 2012-06-08 2015-11-30 Шир Хьюман Дженетик Терапис, Инк. ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
EA201591283A1 (ru) 2013-03-14 2016-02-29 Шир Хьюман Дженетик Терапис, Инк. Количественная оценка эффективности кэп матричной рнк
ES2967701T3 (es) 2013-03-15 2024-05-03 Translate Bio Inc Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas
SG10201801428RA (en) 2013-08-21 2018-03-28 Curevac Ag Method for increasing expression of rna-encoded proteins
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
AU2014375402B2 (en) 2013-12-30 2020-10-01 CureVac SE Artificial nucleic acid molecules
WO2016004318A1 (en) 2014-07-02 2016-01-07 Shire Human Genetic Therapies, Inc. Encapsulation of messenger rna
EP4023755B1 (en) 2014-12-12 2023-04-26 CureVac SE Artificial nucleic acid molecules for improved protein expression
WO2016174271A1 (en) 2015-04-30 2016-11-03 Curevac Ag Immobilized poly(n)polymerase
RS64331B1 (sr) 2015-06-19 2023-08-31 Massachusetts Inst Technology Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta
WO2017162265A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
US20180153822A1 (en) 2016-11-10 2018-06-07 Translate Bio, Inc. Process of Preparing mRNA-Loaded Lipid Nanoparticles
CN116549671A (zh) 2016-11-10 2023-08-08 川斯勒佰尔公司 用于递送mrna的改进的基于ice的脂质纳米颗粒制剂
WO2018189372A1 (en) * 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
CN112584858A (zh) 2018-04-03 2021-03-30 赛诺菲 抗原性ospa多肽
AU2020315962B2 (en) 2019-07-23 2026-02-12 Translate Bio, Inc. Stable compositions of mRNA-loaded lipid nanoparticles and processes of making
CA3162019A1 (en) * 2019-12-20 2021-06-24 Gemma NAVARRO Lipid nanoparticles for delivery of nucleic acids
AU2021269042A1 (en) 2020-05-07 2023-02-02 Translate Bio, Inc. Optimized nucleotide sequences encoding SARS-CoV-2 antigens

Similar Documents

Publication Publication Date Title
Kelly et al. Enabling sublingual peptide immunization with molecular self-assemblies
KR100554344B1 (ko) 소포성 복합체와 이의 제조 및 사용방법
CN112384205B (zh) 信使rna疫苗及其用途
JP2023527309A5 (cg-RX-API-DMAC10.html)
JP2023522249A5 (cg-RX-API-DMAC10.html)
JP2022543038A5 (cg-RX-API-DMAC10.html)
JP2000516200A (ja) ウシの呼吸病に対するポリヌクレオチドワクチン処方
NZ306483A (en) Composition for inducing a mucosal immune response administered by two different routes
JP2023531511A5 (cg-RX-API-DMAC10.html)
WO2000047186A1 (en) Polynucleotide compositions for intramuscular and intradermal administration
Scaria et al. mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response
Le Guen et al. Gene transfer to skeletal muscle using hydrodynamic limb vein injection: Current applications, hurdles and possible optimizations
US7256180B2 (en) Compositions and methods for inducing activation of dendritic cells
KR102190180B1 (ko) Dna 백신
Zhang et al. A synthetic cyclic peptide for promoting antigen presentation and immune activation
CN120500351A (zh) 呼吸道合胞病毒mRNA疫苗
CN120202020A (zh) 工程化水痘带状疱疹病毒带状疱疹mRNA疫苗
US12390485B2 (en) Compounds and methods for suppressing an immune response to substances containing polyethylene glycol
CN101455846A (zh) 脱乙酰壳聚糖递送系统组装的结核基因疫苗及其制备和应用
CN119818665A (zh) 新型发热伴血小板减少综合征病毒疫苗
JP2003519089A (ja) 肺炎球菌表面型蛋白質配合ワクチン
EP0669941A1 (en) Method of reducing multidrug resistance in cells and tissues
CN120390752A (zh) 靶向具有半胱天冬酶激活和募集结构域(asc)的凋亡相关斑点样蛋白的组合物及使用方法
AU2023233145A1 (en) Peptide-based delivery of agents
WO2024021817A1 (zh) 新型冠状病毒疫苗及其制备方法和应用